Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
about
Recent advances of novel targeted therapy in non-small cell lung cancerAssociation of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewChemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancerEGFR targeted therapy in non-small cell lung cancer: potential role of cetuximabFirst-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerThe Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled TrialsCombining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLCStrengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials.The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancerEGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapyCFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancerUnderstanding resistance to EGFR inhibitors-impact on future treatment strategiesEGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324.Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysisIndirect comparison of the efficacy and safety of gefitinib and cetuximab-based therapy in patients with advanced non-small-cell lung cancer.New trends in epidermal growth factor receptor-directed monoclonal antibodies.The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials.Rash rates with egfr inhibitors: meta-analysis.Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes.Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?Cetuximab in non-small-cell lung cancerSquamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.Targeted therapies for non-small cell lung cancer: an evolving landscape.The risk for anemia with targeted therapies for solid tumorsCA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.Cetuximab and biomarkers in non-small-cell lung carcinomaRole of epidermal growth factor receptor in acute and chronic kidney injury.ANGPTL2/LILRB2 signaling promotes the propagation of lung cancer cells.Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesEpidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysisImproving Outcomes in Advanced Lung Cancer: Maintenance therapy in non-small-cell lung carcinoma.Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies
P2860
Q21092930-522CAB66-D47A-4519-A032-E7624D668B36Q21198850-8E41DD66-0704-4F82-ABDA-93937A5474B5Q24187972-3BDCEDAF-81F5-49B7-A8F7-5FE43DE2BC24Q24652337-A121D38F-5AF8-49E5-85D9-27F1BBE9E73DQ26471909-BDD1B773-F3A7-451C-B0A4-078F06BD0E10Q26796549-140FE178-A4B4-4006-B5A9-DD09E9C1F3A4Q26852202-8E2279EE-4DB4-4790-8E64-F99E1331D3A9Q31050197-55EC725F-CAB8-48EA-A25B-F72E6A6DC0FFQ33565294-55DD395A-BB69-4A43-A7E2-819E05DF77F3Q33574958-723D506E-F7F5-43BC-ADE2-1B1F6E418232Q33704088-99CD8DEF-FD94-4C76-98B1-BC50B51576A1Q33885578-A8634B2F-2D32-4771-8BCC-FA446852FA4DQ34023291-971EBDD1-3A9C-458B-9637-90D0FE52FCD5Q34088424-382E01CC-6F39-4B92-AC8B-FD9A32B4BC6EQ34216725-085E4B61-0DDE-4895-BB8E-81EDB67B0100Q34488787-1B2BAA28-CD18-48BE-A203-0123B330EE23Q34537664-84FBEE96-6DF0-4F26-BAB6-FF2B526CB810Q34608124-1457B1B1-EF44-4A7F-ACE1-96897EC32F59Q34621577-154035B6-31FA-4534-B6EE-E7D02F93AB18Q34685531-0755B601-1DC4-4D6B-B36D-2E6498782D6DQ34761646-AC809D15-BE37-4E98-AB15-EACF9587A148Q34773458-001708D0-6152-4624-A229-075EB22B7E53Q35001415-5187331D-375A-4E8F-AA44-399FCECFD6C6Q35023433-22FD49CF-8173-4D83-A913-1A56A532D72EQ35146923-837BD3C4-131D-483A-854E-45E7D4EA8F9CQ35170255-529DD5C2-2254-4D97-9651-350095432695Q35200322-17E10EBE-DBD2-45CF-92D1-0017CD2C1D59Q35200393-91CC5110-8CEE-4783-ADA4-F10A77645765Q35220347-91818C2A-EB41-45D3-9499-94505D1904B6Q35628597-B0FAEC69-392D-468B-A23D-F0D3FACD2894Q35989994-1BD96CCB-896F-4F2F-88DD-49D8BF3D9D2CQ36012730-8662B769-8DDF-4F00-9E84-B68B277E77D0Q36171281-F6AD4FC8-2721-4083-AF82-9E619E21A262Q36224457-55C39182-D6A5-4CD5-8F6C-6A1827FDE499Q36356225-1460B590-762E-4DB6-AFBE-EE9B0CED93E4Q36412597-78EF2B9D-2B5F-4E1A-9307-9E3B8E8858FDQ36482542-361D5DD7-9368-424A-940F-50FE91676AAAQ36649908-40923C50-EAFC-4DA8-B481-F8354668B53CQ36741073-459651B1-0D34-41A3-B695-1B3E71FD962EQ36850900-5CFD2E41-9A5D-4DA1-B655-C549E65EA718
P2860
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Randomized phase II study of c ...... ed non-small-cell lung cancer.
@en
Randomized phase II study of c ...... ed non-small-cell lung cancer.
@nl
type
label
Randomized phase II study of c ...... ed non-small-cell lung cancer.
@en
Randomized phase II study of c ...... ed non-small-cell lung cancer.
@nl
prefLabel
Randomized phase II study of c ...... ed non-small-cell lung cancer.
@en
Randomized phase II study of c ...... ed non-small-cell lung cancer.
@nl
P2093
P356
P1433
P1476
Randomized phase II study of c ...... ced non-small-cell lung cancer
@en
P2093
A Chemaissani
A Szczesna
B C Mennecier
K J O'Byrne
M Constenla
M R Ranson
P304
P356
10.1093/ANNONC/MDM474
P577
2007-10-17T00:00:00Z